Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

• Published in: Blood Vol. 135; no. 13; pp. 1008 - 1018
• Main Authors: Risueño, Alberto, Hagner, Patrick R., Towfic, Fadi, Fontanillo, Celia, Djebbari, Amira, Parker, Joel S., Drew, Clifton P., Nowakowski, Grzegorz S., Maurer, Matthew J., Cerhan, James R., Wei, Xin, Ren, Yan, Lee, Chung-Wein, Couto, Suzana, Wang, Maria, Pourdehnad, Michael, Gandhi, Anita K., Trotter, Matthew W.B.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 26.03.2020; American Society of Hematology
• Subjects: Adult; Aged; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biopsy; Computational Biology - methods; Female; Fluorescent Antibody Technique; Gene Expression Profiling; Gene Expression Regulation, Neoplastic - drug effects; Gene Regulatory Networks; Humans; Lymphoid Neoplasia; Lymphoma, Large B-Cell, Diffuse - diagnosis; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Male; Middle Aged; Reproducibility of Results; Transcriptome
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood.2019002414

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, commonly described by cell-of-origin (COO) molecular subtypes. We sought to identify novel patient subgroups through an unsupervised analysis of a large public dataset of gene expression profiles from newly diagnosed de novo DLBCL patients, yielding 2 biologically distinct subgroups characterized by differences in the tumor microenvironment. Pathway analysis and immune deconvolution algorithms identified higher B-cell content and a strong proliferative signal in subgroup A and enriched T-cell, macrophage, and immune/inflammatory signals in subgroup B, reflecting similar biology to published DLBCL stratification research. A gene expression classifier, featuring 26 gene expression scores, was derived from the public dataset to discriminate subgroup A (classifier-negative, immune-low) and subgroup B (classifier-positive, immune-high) patients. Subsequent application to an independent series of diagnostic biopsies replicated the subgroups, with immune cell composition confirmed via immunohistochemistry. Avadomide, a CRL4CRBN E3 ubiquitin ligase modulator, demonstrated clinical activity in relapsed/refractory DLBCL patients, independent of COO subtypes. Given the immunomodulatory activity of avadomide and the need for a patient-selection strategy, we applied the gene expression classifier to pretreatment biopsies from relapsed/refractory DLBCL patients receiving avadomide (NCT01421524). Classifier-positive patients exhibited an enrichment in response rate and progression-free survival of 44% and 6.2 months vs 19% and 1.6 months for classifier-negative patients (hazard ratio, 0.49; 95% confidence interval, 0.280-0.86; P = .0096). The classifier was not prognostic for rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone or salvage immunochemotherapy. The classifier described here discriminates DLBCL tumors based on tumor and nontumor composition and has potential utility to enrich for clinical response to immunomodulatory agents, including avadomide. •A gene expression classifier separates 2 distinct patient segments in DLBCL that differ in immune cell composition.•The classifier predicts for clinical benefit to avadomide in R/R DLBCL and is not prognostic for progression on immunochemotherapy. [Display omitted]